Physician profile
Ashlynn Zerger
NPI 1760019418
$375.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.89 · 2022: $138 · 2023: $141 · 2024: $13.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.72 | 2021-2023 | |
| Glaxosmithkline, LLC. | $62.38 | 2021-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $26.43 | 2022 | |
| Eisai INC. | $22.84 | 2021 | |
| Hikma Pharmaceuticals USA | $18.33 | 2023 | Ryaltris |
| Amarin Pharma, INC. | $17.93 | 2021 | |
| Pfizer INC. | $17.62 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.18 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $15.79 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.36 | 2023 | Quviviq |
| Antares Pharma, INC. | $14.21 | 2023 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $13.40 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlynn Zerger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.